Managing perianal Crohn's fistula in the anti-TNFα era

Tech Coloproctol. 2015 Nov;19(11):673-8. doi: 10.1007/s10151-015-1332-3. Epub 2015 Aug 12.

Abstract

Perianal fistulas in Crohn's disease are common and difficult to treat. Their aetiology is poorly understood. Assessment is clinical, endoscopic and radiological, and management is undertaken by a multidisciplinary team of gastroenterologists, surgeons and radiologists. Surgical drainage of the fistula tract system with the placement of loose setons precedes combined therapy with immunosuppressant and anti-TNFα agents in most patients. Proctitis should be rigorously eliminated where possible. Definitive surgical repair is sometimes possible and diversion or proctectomy are occasionally required. Combined medical and surgical management represents a promising avenue for the future.

Keywords: Anti-tumour necrosis factor-α; Biological therapies; Crohn’s disease; Perianal fistula; Surgery.

MeSH terms

  • Adalimumab / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Certolizumab Pegol / therapeutic use
  • Combined Modality Therapy / methods
  • Crohn Disease / complications*
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Infliximab / therapeutic use
  • Patient Care Team
  • Rectal Fistula / classification
  • Rectal Fistula / etiology
  • Rectal Fistula / therapy*
  • Remission Induction / methods
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Anti-Inflammatory Agents
  • Gastrointestinal Agents
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Certolizumab Pegol